Inclisiran Phase 3 Trials for Elevated LDL Cholesterol Results Published

By Hipa.ai Research · January 1, 2020

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

Pivotal Phase 3 trial results for inclisiran in patients with elevated low-density lipoprotein (LDL) cholesterol were published on January 1, 2020. These findings, detailed in the New England Journal of Medicine, describe the outcomes of two key studies evaluating the drug's efficacy and safety in this patient population.

Background

Inclisiran is a drug developed to address elevated low-density lipoprotein (LDL) cholesterol. High LDL cholesterol levels are a significant risk factor for cardiovascular diseases, including atherosclerotic cardiovascular disease (ASCVD). The publication of these Phase 3 trial results marks a crucial step in understanding inclisiran's potential role in managing this condition.

Trial design

The published article details results from two pivotal Phase 3 trials involving inclisiran. One of these studies, specifically mentioned as ORION-11, investigated inclisiran in subjects with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents who also presented with elevated low-density lipoprotein cholesterol. These trials aimed to assess the drug's impact on LDL cholesterol levels in these high-risk populations.

What this means

The publication of pivotal Phase 3 trial results for inclisiran in patients with elevated LDL cholesterol is a significant development for clinicians and researchers. While specific outcome measurements are not detailed in this event summary, the publication in a reputable journal like the New England Journal of Medicine indicates that comprehensive data on inclisiran's performance has been made available to the scientific community. These findings are critical for evaluating inclisiran's potential as a therapeutic option for individuals at risk due to high LDL cholesterol, including those with ASCVD or ASCVD-risk equivalents. The availability of this data allows for thorough review and discussion of the drug's efficacy, safety profile, and overall clinical utility.

Source

The information regarding the publication of these trial results was obtained from PubMed, a database of biomedical literature. The article, titled "Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol," was published on January 1, 2020, and is accessible via pubmed.ncbi.nlm.nih.gov.